I am expecting my Master’s degree in Medicinal Chemistry from Duquesne University (Pittsburgh, PA) in just a few months, and hopefully the following information will allow me to go one step further in pursuing admission into the M.S. program in Biostatistics at the University of XXXXX. My career goal is to be a data analyst in health research and policy; where I will be able to apply my knowledge in statistics and pharmacy to make my contribution to the health care industry, and where I can support myself by doing what I actually love.
Having lived in the States for three years, acculturation has been a bewildering, refreshing and exciting course for me. With new perspectives, new perceptions, and new understandings, I’ve been seeing things very differently. As people say, “in doing, we learn.” During the time I was learning to perform at a Christmas dinner party, to appreciate the amusing and witty comments from lecture professors, to raft and canyoning with my American friends, and to paint my own apartment, I also came to realize that a career in health research and policy as well as drug discovery and development is an evolving process of understanding new trends.
My research experiences were primarily concerned with the creation of new synthetic drug compounds as well as preclinical ADME studies. I started my education in pharmacy at Fudan University (Shanghai, China) years ago, and had my first lab experience when doing my undergraduate graduation thesis project: “Suksdorfin and DCP analogs as potent anti-HIV agents.” In 2009, I had another opportunity for a three-month exchange program at National Tsing Hua University (Hsinchu, Taiwan). I worked in Dr. Hsing-Wen Sung’s lab conducted a project at the chemical engineering department on a project: “Chitosan-coated PLGA nanoparticles for drug delivery.” Later on in fall 2010, I came to Dr. Gangjee's group at Duquesne University to start my graduate studies, and have been conducting my thesis project “Pyrimido-indole analogs as antimitotic agents in fight of breast cancer.” My work mainly involved designing and optimizing new synthetic routes, identifying and characterizing new compounds, developing cell/animal testing methodology, and SAR researching. It all centered around synthesizing new chemical entities and determining critical parameters for their druggability (potentiality to become a drug). In brief, Medicinal Chemistry is the first stage in drug discovery and development.
Nevertheless, “drug discovery and development is becoming and will continue to be fundamentally different,” quote by Richard Allen, MD. Firstly, as the industry is maturing, major drug companies have become increasingly risk averse, committing to acquire compounds only in later stages of development. Moreover, recent progress in quantitative structure-activity relationship (QSAR), combination chemistry, high throughput screening (HTS), and the human genome project, booming the search...